These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Rasagiline in Parkinson's disease: the show must go on. Jost WH Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684 [No Abstract] [Full Text] [Related]
25. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Olanow CW Neurology; 2009 Feb; 72(7 Suppl):S59-64. PubMed ID: 19221316 [TBL] [Abstract][Full Text] [Related]
30. The comparative effects of medical therapies for Parkinson's disease. Horn S; Stern MB Neurology; 2004 Oct; 63(7 Suppl 2):S7-12. PubMed ID: 15477585 [No Abstract] [Full Text] [Related]
31. The fabulous neuroprotection of selegiline: memoir and prospectus. Landau WM J Child Neurol; 2010 Oct; 25(10):1302-4. PubMed ID: 20940135 [No Abstract] [Full Text] [Related]
32. Monoamine oxidase inhibitors--is it time to up the TEMPO? Rascol O Lancet Neurol; 2003 Mar; 2(3):142-3. PubMed ID: 12849233 [No Abstract] [Full Text] [Related]
33. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease. Jost WH; Friede M; Schnitker J Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3349. PubMed ID: 25491607 [No Abstract] [Full Text] [Related]
34. Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Stocchi F Int J Clin Pract; 2006 Feb; 60(2):215-21. PubMed ID: 16451296 [TBL] [Abstract][Full Text] [Related]
35. [Are there innovations in the treatment of Parkinson's disease?]. Ludin HP Praxis (Bern 1994); 2004 Nov; 93(45):1865-8. PubMed ID: 15571301 [TBL] [Abstract][Full Text] [Related]
36. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Fernandez HH; Chen JJ Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937 [TBL] [Abstract][Full Text] [Related]